|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-4-16
|
|
pubmed:abstractText |
Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CassCarol ECE,
pubmed-author:DemetterPieterP,
pubmed-author:DevièreJacquesJ,
pubmed-author:LaiRaymondR,
pubmed-author:MackeyJohn RJR,
pubmed-author:MaréchalRaphaëlR,
pubmed-author:PeetersMarcM,
pubmed-author:PolusMarcM,
pubmed-author:SalmonIsabelleI,
pubmed-author:Van LaethemJean-LucJL,
pubmed-author:YoungJamesJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2913-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19318496-Adenocarcinoma,
pubmed-meshheading:19318496-Adult,
pubmed-meshheading:19318496-Aged,
pubmed-meshheading:19318496-Aged, 80 and over,
pubmed-meshheading:19318496-Chemotherapy, Adjuvant,
pubmed-meshheading:19318496-Clinical Trials, Phase I as Topic,
pubmed-meshheading:19318496-Deoxycytidine,
pubmed-meshheading:19318496-Equilibrative Nucleoside Transporter 1,
pubmed-meshheading:19318496-Female,
pubmed-meshheading:19318496-Follow-Up Studies,
pubmed-meshheading:19318496-Humans,
pubmed-meshheading:19318496-Male,
pubmed-meshheading:19318496-Membrane Transport Proteins,
pubmed-meshheading:19318496-Middle Aged,
pubmed-meshheading:19318496-Multivariate Analysis,
pubmed-meshheading:19318496-Neoplasm Recurrence, Local,
pubmed-meshheading:19318496-Pancreatic Neoplasms
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepato-Pancreatology, Gastrointestinal Cancer Unit, and Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. rmarecha@ulb.ac.be
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
